What is claimed is:
1. A method of heat treatment of a card-shaped recording medium, having at least a base member, an ink-receiving layer, and an ink-permeable outermost layer formed on the base member to make the ink-permeable outermost layer impermeable to ink by means of a heating member, wherein the heat treatment is conducted under the conditions that the temperature of the heating member is higher than the glass transition temperature of the base member material, and the temperature at the half-depth position in the base member is not higher than the glass transition temperature thereof.
2. The method of heat treatment according to claim 1, wherein the heat treatment is conducted by bringing the heating member into contact locally with a portion of the card-shaped recording medium, and scanning continuously the card-shaped recording medium with the heating member.
3. The method of heat treatment according to claim 1, wherein the heating member is comprised of opposing rollers, and the heat treatment is conducted with the heating member by feeding the card-shaped recording medium at a constant linear speed through the heating member to press and heat-treating the card-shaped recording medium.
4. The method of heat treatment according to claim 2, wherein the heating member is comprised of opposing rollers, and the heat treatment is conducted with the heating member by feeding the card-shaped recording medium at a constant linear speed through the heating member to press and heat-treating the card-shaped recording medium.
5. The method of heat treatment according to claim 1, wherein the heating member is in a shape of a film or sheet, a heater having a linear heating element slides on one face of the film or sheet, and the other face moves in contact with the card-shaped recording medium.
6. The method of heat treatment according to claim 2, wherein the heating member is in a shape of a film or sheet, a heater having a linear heating element slides on one face of the film or sheet, and the other face moves in contact with the card-shaped recording medium.
7. The method of heat treatment according to claim 1, wherein the face of the heating member is made of an elastic material.
8. The method of heat treatment according to claim 2, wherein the face of the heating member is made of an elastic material.
9. The method of heat treatment according to claim 3, wherein the face of the heating member is made of an elastic material.
10. The method of heat treatment according to claim 4, wherein the face of the heating member is made of an elastic material.
11. The method of heat treatment according to claim 5, wherein the face of the heating member is made of an elastic material.
12. The method of heat treatment according to claim 6, wherein the face of the heating member is made of an elastic material.
13. The method of heat treatment according to claim 1, wherein a material of the base member is selected from vinyl chloride resins, vinylidene chloride resins, vinyl acetate resins, polyethylene resins, polypropylene resins, methacrylic resins, ABS resins, polycarbonate resins, glycol-modified polyethylene terephthalate resins, polymer blends thereof, and copolymers of the corresponding monomers.
14. The method of heat treatment according to claim 1, wherein a material of the outermost layer is composed of fine particles of a thermoplastic resin.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method of inhibiting an inflammatory response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of Hsp 27.
2. A method of inducing IL-10 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
3. A method of inducing IL-12 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
4. A method of simultaneously inducing IL-10 production and IL-12 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
5. The method of claim 1, wherein the therapeutically effective amount is 1 gkg to 160 gkg.
6. The method of claim 5, wherein the therapeutically effective amount is 2 gkg to 80 gkg.
7. The method of claim 6, wherein the therapeutically effective amount is 4 gkg to 40 gkg.
8. An anti-inflammatory composition comprising an effective amount of Hsp 27 and a pharmaceutically acceptable carrier.
9. A method of promoting dendritic cell maturation, the method comprising:
isolating monocytes from blood without triggering activation;
culturing the monocytes ex vivo;
inducing conversion of the monocytes into immature dendritic cells; and
contacting the dendritic cells with an effective amount of Hsp27 for an effective length of time,
thereby promoting maturation of the dendritic cells.
10. The method of claim 9, wherein inducing conversion of the monocytes into immature dendritic cells comprises culturing the monocytes in a medium comprising IL-4 and GMCSF for an effective conversion time.
11. The method of claim 10, wherein the effective conversion time is 2 to 5 days.
12. The method of claim 9, wherein the effective amount of Hsp27 is 0.1 gml to 500 gml.
13. The method of claim 9, wherein the effective amount of Hsp27 is 1 g to 100 g.
14. The method of claim 9, wherein the effective amount of Hsp27 is 5 g to 50 g.
15. A method of enhancing an immune system response in a human patient, the method comprising:
collecting a sample of blood from the patient;
isolating monocytes from the blood without triggering activation of the monocytes;
culturing the monocytes ex vivo;
inducing conversion of the monocytes into immature dendritic cells;
promoting maturation of the dendritic cells by contacting the dendritic cells with an effective amount of Hsp27 for an effective length of time; and
reintroducing the dendritic cells into the patient.
16. The method of claim 15, further comprising the step of contacting the dendritic cells with an antigen after promoting maturation of the dendritic cells, and before reintroducing the dendritic cells into the patient.
17. The method of claim 16, wherein the antigen is selected from the group consisting of a human tumor antigen, a bacterial antigen, and a viral antigen.